CellaVision Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

CellaVision wird ein jährliches Gewinn- und Umsatzwachstum von 24% bzw. 13.7% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 24.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 23.9% betragen.

Wichtige Informationen

24.2%

Wachstumsrate der Gewinne

24.2%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	27.0%
Wachstumsrate der Einnahmen	13.1%
Zukünftige Eigenkapitalrendite	23.6%
Analystenabdeckung	Low
Zuletzt aktualisiert	26 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

CellaVision AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Jul 24

Earnings Beat: CellaVision AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Feb 10

Recent updates

CellaVision AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Jul 24

CellaVision AB (publ)'s (STO:CEVI) Intrinsic Value Is Potentially 46% Above Its Share Price

Apr 09

CellaVision (STO:CEVI) Will Pay A Dividend Of SEK2.25

Mar 28

CellaVision's (STO:CEVI) Dividend Will Be SEK2.25

Mar 14

CellaVision (STO:CEVI) Will Pay A Dividend Of SEK2.25

Feb 29

After Leaping 28% CellaVision AB (publ) (STO:CEVI) Shares Are Not Flying Under The Radar

Feb 16

CellaVision (STO:CEVI) Will Pay A Dividend Of SEK2.25

Feb 12

Earnings Beat: CellaVision AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Feb 10

CellaVision's (STO:CEVI) Returns On Capital Not Reflecting Well On The Business

Dec 13

Is Now An Opportune Moment To Examine CellaVision AB (publ) (STO:CEVI)?

Sep 14

Calculating The Intrinsic Value Of CellaVision AB (publ) (STO:CEVI)

Aug 22

CellaVision (STO:CEVI) Is Reinvesting At Lower Rates Of Return

Jun 17

CellaVision's (STO:CEVI) Upcoming Dividend Will Be Larger Than Last Year's

May 07

Estimating The Fair Value Of CellaVision AB (publ) (STO:CEVI)

Apr 19

CellaVision (STO:CEVI) Is Increasing Its Dividend To SEK2.25

Apr 05

CellaVision (STO:CEVI) Is Paying Out A Larger Dividend Than Last Year

Mar 04

CellaVision AB (publ) (STO:CEVI) Analysts Are More Bearish Than They Used To Be

Feb 11

Is CellaVision (STO:CEVI) A Risky Investment?

Jan 13

Is CellaVision AB (publ) (STO:CEVI) Potentially Undervalued?

Dec 13

CellaVision (STO:CEVI) Seems To Use Debt Rather Sparingly

Sep 23

CellaVision (STO:CEVI) May Have Issues Allocating Its Capital

Aug 16

Calculating The Intrinsic Value Of CellaVision AB (publ) (STO:CEVI)

Aug 02

We Ran A Stock Scan For Earnings Growth And CellaVision (STO:CEVI) Passed With Ease

Jun 27

What Is CellaVision AB (publ)'s (STO:CEVI) Share Price Doing?

May 31

CellaVision (STO:CEVI) Could Easily Take On More Debt

Apr 28

Calculating The Intrinsic Value Of CellaVision AB (publ) (STO:CEVI)

Apr 07

Gewinn- und Umsatzwachstumsprognosen

OM:CEVI - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (SEK Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	1,001	261	213	287	3
12/31/2025	871	209	158	234	4
12/31/2024	762	160	159	236	4
6/30/2024	726	145	183	261	N/A
3/31/2024	708	141	168	249	N/A
12/31/2023	677	130	110	196	N/A
9/30/2023	629	112	60	148	N/A
6/30/2023	602	97	23	106	N/A
3/31/2023	616	99	38	118	N/A
12/31/2022	639	118	68	137	N/A
9/30/2022	651	126	93	155	N/A
6/30/2022	642	142	114	173	N/A
3/31/2022	594	135	87	171	N/A
12/31/2021	566	125	75	160	N/A
9/30/2021	532	114	62	139	N/A
6/30/2021	488	101	13	87	N/A
3/31/2021	471	98	44	82	N/A
12/31/2020	471	89	37	71	N/A
9/30/2020	490	85	40	71	N/A
6/30/2020	498	89	80	107	N/A
3/31/2020	492	92	68	90	N/A
12/31/2019	462	99	107	126	N/A
9/30/2019	423	104	94	114	N/A
6/30/2019	412	104	87	107	N/A
3/31/2019	391	97	98	119	N/A
12/31/2018	365	89	51	74	N/A
9/30/2018	330	76	67	91	N/A
6/30/2018	307	67	52	77	N/A
3/31/2018	294	63	N/A	69	N/A
12/31/2017	309	70	N/A	88	N/A
9/30/2017	306	70	N/A	93	N/A
6/30/2017	313	78	N/A	89	N/A
3/31/2017	300	75	N/A	86	N/A
12/31/2016	265	60	N/A	76	N/A
9/30/2016	254	57	N/A	54	N/A
6/30/2016	260	66	N/A	80	N/A
3/31/2016	246	55	N/A	59	N/A
12/31/2015	239	53	N/A	88	N/A
9/30/2015	250	49	N/A	70	N/A
6/30/2015	223	30	N/A	49	N/A
3/31/2015	226	34	N/A	53	N/A
12/31/2014	217	31	N/A	40	N/A
9/30/2014	209	33	N/A	59	N/A
6/30/2014	207	36	N/A	47	N/A
3/31/2014	189	26	N/A	49	N/A
12/31/2013	180	19	N/A	27	N/A
9/30/2013	165	3	N/A	11	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CEVIDas prognostizierte Gewinnwachstum (24% pro Jahr) liegt über der Sparquote (1%).

Ertrag vs. Markt: CEVIDie Erträge des Unternehmens (24% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Swedish (14.1% pro Jahr).

Hohe Wachstumserträge: CEVIEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: CEVIDie Einnahmen des Unternehmens (13.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Swedish (1.9% pro Jahr).

Hohe Wachstumseinnahmen: CEVIDie Einnahmen des Unternehmens (13.7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: CEVIDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (23.9%)

CellaVision Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

CellaVision AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Earnings Beat: CellaVision AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Price target increased by 21% to kr232

Consensus EPS estimates fall by 13%

Price target decreased by 8.0% to kr203

Price target increased by 8.6% to kr220

Recent updates

Now 23% undervalued

Founder & Director recently sold kr27m worth of stock

CellaVision AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Now 21% undervalued

Is CellaVision (STO:CEVI) A Risky Investment?

Does CellaVision (STO:CEVI) Deserve A Spot On Your Watchlist?

Investor sentiment improves as stock rises 15%

Upcoming dividend of kr2.25 per share

First quarter 2024 earnings released: EPS: kr1.26 (vs kr0.81 in 1Q 2023)

Full year 2023 earnings: EPS and revenues exceed analyst expectations

CellaVision (STO:CEVI) Is Due To Pay A Dividend Of SEK2.25

CellaVision AB (publ)'s (STO:CEVI) Intrinsic Value Is Potentially 46% Above Its Share Price

CellaVision (STO:CEVI) Will Pay A Dividend Of SEK2.25

CellaVision's (STO:CEVI) Dividend Will Be SEK2.25

CellaVision (STO:CEVI) Will Pay A Dividend Of SEK2.25

Now 22% undervalued

Now 21% undervalued

After Leaping 28% CellaVision AB (publ) (STO:CEVI) Shares Are Not Flying Under The Radar

CellaVision (STO:CEVI) Will Pay A Dividend Of SEK2.25

Earnings Beat: CellaVision AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Dividend of kr2.25 announced

Price target increased by 21% to kr232

Consensus EPS estimates fall by 13%

Investor sentiment improves as stock rises 30%

Now 21% undervalued

CellaVision's (STO:CEVI) Returns On Capital Not Reflecting Well On The Business

Now 21% undervalued after recent price drop

Investor sentiment improves as stock rises 18%

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

CellaVision AB (publ) to Report Nine Months, 2024 Results on Oct 24, 2024

CellaVision AB (publ) to Report Q3, 2023 Results on Oct 25, 2023

Price target decreased by 8.0% to kr203

Is Now An Opportune Moment To Examine CellaVision AB (publ) (STO:CEVI)?

Now 21% undervalued after recent price drop

Calculating The Intrinsic Value Of CellaVision AB (publ) (STO:CEVI)

Price target increased by 8.6% to kr220

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improves as stock rises 17%

CellaVision AB (publ) to Report Q2, 2023 Results on Jul 20, 2023

Investor sentiment deteriorates as stock falls 17%

CellaVision (STO:CEVI) Is Reinvesting At Lower Rates Of Return

CellaVision's (STO:CEVI) Upcoming Dividend Will Be Larger Than Last Year's

Cellavision AB (Publ) Approves Dividend, Payable on May 12, 2023

Upcoming dividend of kr2.25 per share at 1.3% yield

Consensus EPS estimates increase by 13%

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 11%

Estimating The Fair Value Of CellaVision AB (publ) (STO:CEVI)

Price target decreased by 11% to kr223

Full year 2022 earnings: EPS and revenues miss analyst expectations

CellaVision (STO:CEVI) Is Increasing Its Dividend To SEK2.25

Now 22% undervalued after recent price drop

CellaVision (STO:CEVI) Is Paying Out A Larger Dividend Than Last Year

Now 21% undervalued after recent price drop

Founder & Director recently bought kr63k worth of stock

CellaVision AB (publ) (STO:CEVI) Analysts Are More Bearish Than They Used To Be

Full year 2022 earnings released: EPS: kr4.96 (vs kr5.26 in FY 2021)

Cellavision AB (Publ) Proposes Dividend for 2022

Now 23% undervalued

Investor sentiment improves as stock rises 15%

Is CellaVision (STO:CEVI) A Risky Investment?

Now 21% undervalued after recent price drop

Investor sentiment improved over the past week

Is CellaVision AB (publ) (STO:CEVI) Potentially Undervalued?

Now 21% undervalued after recent price drop

CellaVision AB (publ) Announces the Appointment of Emil Hjalmarsson as Chairman of the Nomination Committee

Price target decreased to kr253

Investor sentiment deteriorated over the past week